EU/3/06/409: Orphan designation for the treatment of acute lymphoblastic leukaemia

L-asparaginase encapsulated in erythrocytes

Table of contents


On 27 October 2006, orphan designation (EU/3/06/409) was granted by the European Commission to Erytech Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes for the treatment of acute lymphoblastic leukaemia.

Key facts

Active substance
L-asparaginase encapsulated in erythrocytes
Intended use
Treatment of acute lymphoblastic leukaemia
Orphan designation status
EU designation number
Date of designation
Erytech Pharma S.A.
60, avenue Rockefeller
69008 Lyon
Telephone: +33 4 78 74 44 38
Telefax: +33 4 78 75 56 29

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating